# Alimentary Pharmacology & Therapeutics

VOLUME 16 PAGES 1–2148 2002

*Editors*
R E Pounder and W L Peterson

*Editorial Board*

*Chairman* J-R Malagelada
R Arnold
A T R Axon
K D Bardhan
G Bianchi Porro
H G Dammann
G Delle Fave
B M Fennerty
R L Fisher
A G Fraser
N J Greenberger
E G Hahn
S B Hanauer
C J Hawkey
P Hayes
R V Heatley
H J F Hodgson
G J Holtmann
C W Howden
R Hunt
D P Jewell
K Kawai
K Kimura
G J Krejs
S K Lam
R Lambert
C B H W Lamers
M J S Langman
D A Lieberman
P Malfertheiner
D C Metz
M Mignon
S Okabe
C O'Morain
D S Rampton
J Rask-Madsen
J M Rhodes
J Rodes
P Rutgeerts
P Schoenfeld
F Shanahan
R A Smallwood
A Sonnenberg
R Spiller
V Stanghellini
R W Stockbrugger
J J Y Sung
N J Talley
A Terano
W J Tremaine
G N Tytgat
N Vakil
J L Wallace
R P Walt
M Wolfe
S-D Xiao

**Blackwell**
Publishing

© 2002 Blackwell Publishing
Published by Blackwell Publishing Ltd
Osney Mead, Oxford OX2 0EL
23 Ainslie Place, Edinburgh EH3 6AJ

Other Editorial Offices:
Blackwell Publishing Inc., Commerce Place, 350 Main Street, Malden, MA 02148-5018, USA
Blackwell Asia, 550 Swanston Street, Carlton South, Victoria 3053, Australia
Blackwell Munksgaard, 1, Rosenoms Allè, P.O. Box 227, DK-1502 Copenhagen V, Denmark
Blackwell Verlag, Kurfürstendamm 57, D-10707 Berlin (Charlottenburg) Germany
Blackwell Publishing Japan, Blackwell Publishing KK, Healthcare Division, NK Bldg, 3F, 2-8-12 Iwamotocho, Chiyodaku, Tokoyo 101-0032, Japan

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Centre (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01973, USA. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to the Editor, *Alimentary Pharmacology & Therapeutics*. ISSN 0269–2813/02 $15.00

*Alimentary Pharmacology & Therapeutics* is included in the major information retrieval systems, including Index Medicus and Medline, the CINAHL index, CABS Science Citation Index, Current Contents—Life Sciences, Excerpta Medica and Current Opinion in Gastroenterology

ISSN 0269–2813
Typset by SPS, Chennai, India, and printed at Bell & Bain, Glasgow, UK

# Contents

VOLUME 16 NUMBER 1 JANUARY

1 Review article: non-surgical treatment of hepatocellular carcinoma. *A. M. Aisowmely & H. J. F. Hodgson*

17 Review article: transient lower oesophageal sphincter relaxations—a pharmacological target for gastro–oesophageal reflux disease? *D. P. Hirsch, G. N. J. Tytgat & G. E. E. Boeckxstaens*

27 Budesonide enema in pouchitis—a double-blind, double-dummy, controlled trial. *A. Sambuelli, I. Boerr, S. Negreira, A. Gil, G. Camartino, S. Huernos, Z. Kogan, A. Cabanne, A. Graziano, A. Peredo, I. Doldán, O. Gonzalez, E. Sugai, M. Lumi & J. C. Bai*

35 Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. *M. Frazzoni, E. De Micheli, A. Grisendi & V. Savarino*

41 Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. *A. Sonnenberg, A. Soni & R. E. Sampliner*

51 The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. *E. V. Loftus Jr, P. Schoenfeld & W. J. Sandborn*

61 A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. *J. R. B. Green, J. C. Mansfield, J. A. Gibson, G. D. Kerr & P. C. Thornton*

69 A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. *J. C. Mansfield, M. H. Giaffer, P. A. Cann, D. Mckenna, P. C. Thornton & C. D. Holdsworth*

79 Interaction between azathioprine and aminosalicylates: an *in vivo* study in patients with Crohn's disease. *O. Dewit, R. Vanheuverzwyn, J. P. Desager & Y. Horsmans*

87 Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicenter randomized, double-blind studies. *G. N. J. Sytgat, L. Van Nueten, I. Van de Velde, A. Joslyn & S. B. Hanauer*

101 Topical mononitrate treatment in patients with anal fissure. *L. Tankova, K. Yoncheva, M. Muhtarov, H. Kadyan & V. Draganov*

105 Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines. *G. Manes, A. Balzano, P. Marone, M. Lioniello & S. Mosca*

111 Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide. *T. Hashimoto, K. Adachi, N. Ishimura, K. Hirakawa, T. Katsube, A. Kurotani, S. Hattori & Y. Kinoshita*

119 Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? *P. Netzer, C. Gaia, S. T. Lourens, P. Reber, S. Wildi, U. Noelpp, E. P. Ritter, H. Ledermann, D. Lüscher, L. Varga, J. A. Kinser, M. W. Büchler & U. Scheurer*

129 Dose-related effects of motilin on proximal gastrointestinal motility. *I. M. C. Kamerling, A. D. Van Haarst, J. Burggraaf, H. C. Schoemaker, I. Biemond, R. Jones, A. F. Cohen & A. A. A. Masclee*

137 Impact of intravenous omeprazole on *Helicobacter pylori* eradication by triple therapy in patients with peptic ulcer bleeding. *B.-S. Sheu, C.-H. Chi, C.-C. Huang, A.-W. Kao, Y.-L. Wang & H.-B. Yang*

145 Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for *Helicobacter pylori* eradication. *I. J. Choi, H. C. Jung, K. W. Choi, J. H. Kim, D. S. Ahn, U. S. Yang, J. S. Rew, S. I. Lee, J. C. Rhee, I. Sik Chung, J. M. Chung & W.-S. Hong*

153 Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of *Helicobacter pylori* infection. *F. Bazzoli, R. M. Zagari, P. Pozzato, S. Fossi, L. Ricciardiello, G. Nicolini, I. De Luca, D. Berretti, G. Alampi, C. Di Pietro, P. Morelli & E. Roda*

159 Treatment with a proton pump inhibitor promotes corpus gastritis in patients with *Helicobacter pylori*-infected antrum-predominant gastritis. *M. Suzuki, H. Suzuki, T. Kitahora, M. Miyazawa, S. Nagahashi, K. Suzuki & H. Ishii*

VOLUME 16 NUMBER 2 FEBRUARY

167 Current concepts in the management of *Helicobacter pylori* infection—The Maastricht 2-2000 Consensus Report. *P. Malfertheiner, F. Mégraud, C. O'Morain, A. P. S. Hungin, R. Jones, A. Axon, D.Y. Graham, G. Tytgat & The European* Helicobacter Pylori *Study Group (EHPSG)*

181 Review article: immunosuppressants in distal ulcerative colitis. *G. Falasco, R. Zinicola & A. Forbes*

189 Review article: single subject trials as a research instrument in gastrointestinal pharmacology. *L. G. Madsen & P. Bytzer*

197 Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an *in vitro* study. *L. Langmead, C. Dawson, C. Hawkins, N. Banna, S. Loo & D. S. Rampton*

207 Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. *N. Mahmud, D. O'Toole, N. O'Hare, P. J. Freyne, D. G. Weir & D. Kelleher*

217 Effects of meal consistency and ingested fluid volume on the intragastric distribution of a drug model in humans—a magnetic resonance imaging study. *H. Faas, A. Steingoetter, C. Feinle, T. Rades, H. Lengsfeld, P. Boesiger, M. Fried & W. Schwizer*

225 Effects of 5-$HT_3$ antagonism on postprandial gastric volume and symptoms in humans. *B. Kuo, M. Camilleri, D. Burton, B. Viramontes, S. McKinzie, G. Thomforde, M. K. O'Connor & B. H. Brinkmann*

235 Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. *G. Marino, V. K. Rustgi, G. Salzberg, L. B. Johnson, P. C. Kuo, J. S. Plotkin & D. A. Flockhart*

243 Interferon-α plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers. *J. A. Moreno-Monteagudo, A. Castro, A. De Pedro, J. A. Lorenzo, M. Fernández-Bermejo, S. Lopez, L. García-Buey, M. J. Borque, J. D. Pedreira & R. Moreno-Otero*

251 Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. *A. S. L. Cheng, H. L. Y. Chan, N. W. Y. Leung, C. T. Liew, K. F. To, P. B. S. Lai & J. J. Y. Sung*

261 The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. *J. J. Ofman, G. H. Dorn, M. B. Fennerty & R. Fass*

275 Effect of *Helicobacter pylori* eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. *J. S. Kim, S. G. Kim, I. J. Choi, M. J. Park, B. G. Kim, H. C. Jung & I. S. Song*

281 *Helicobacter pylori*, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus. *C. E. M. De Block, I. H. De Leeuw, J. J. P. M. Bogers, P. A. Pelckmans, M. M. Ieven, E. A. E. Van Marck, V. Van Hoof, E. Máday, K. L. Van Acker & L. F. Van Gaal*

291 Primary resistance to antibiotics and its clinical impact on the efficacy of *Helicobacter pylori* lansoprazole-based triple therapies. *S. K. Poon, C. S. Chang, J. Su, C. H. Lai, C. C. Yang, G. H. Chen & W. -C. Wang*

297 Nizatidine and cisapride enhance salivary secretion in humans. *K. Adachi, M. Ono, A. Kawamura, M. Yuki, H. Fujishiro & Y. Kinoshita*

303 Minor effects of *Helicobacter pylori* on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors. *B. I. Hirschowitz, J. Simmons & J. Mohnen*

315 High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure *Helicobacter pylori* infection: impact of two second-line therapies in a randomized study. *U. Peitz, M. Sulliga, K. Wolle, A. Leodolter, U. Von Arnim, S. Kahl, M. Stolte, G. Börsch, J. Labenz & P. Malfertheiner*

325 Sulphide-induced energy deficiency in colonic cells is prevented by glucose but not by butyrate. *S. J. Hulin, S. Singh, M. A. S. Chapman, A. Allan, M. J. S. Langman & M. C. Eggo*

VOLUME 16 NUMBER 3 MARCH


333 Review article: the non-inherited gastrointestinal polyposis syndromes. *E. M. Ward & H. C. Wolfsen*

343 Review article: the complexity of drug development for irritable bowel syndrome. *M. A. Kamm*

353 Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? *C. Faivre-Finn, A.-M. Bouvier, E. Mitry, E. Rassiat, F. Clinard & J. Faivre*

361 Flumazenil vs. placeo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. *C. Goulenok, B. Bernard, J. F. Cadranel, D. Thabut, V. Di Martino, P. Opolon & T. Poynard*

373 Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating ß-blocker, in patients with cirrhosis and portal hypertension. *D. Tripathi, G. Therapondos, H. F. Lui, A. J. Stanley & P. C. Hayes*

381 A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon. *A. H. Malik, K. S. Kumar, P. F. Malet, G. Ostapowicz, G. Adams, M. Wood, K. Yarbrough, A. Jones & W. M. Lee*

389 Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. *S. Campbell, K. Kingstone & S. Ghosh*

399 Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. *B. E. Sands, B. D. Winston, B. Salzberg, M. Safdi, C. Barish, L. Wruble, R. Wilkins, M. Shapiro, U. S. Schwertschlag & the rhIL-11 Crohn's Study Group*

407 Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. *W. J. Tremaine, A. Brzezinski, J. A. Katz, D. C. Wolf, T. J. Fleming, J. Mordenti, L. C. Strenkoski-Nix, M. C. Kurth & the Axys Ulcerative Colitis Study Group*

415 A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. *H. Malchow, B. Gertz & the Clafoam Study Group*

425 Acid suppression in healthy subjects following lansoprazole or pantoprazole. *J.-Q. Huang, D. R. Goldwater, A. B. R. Thomson, S. A. Appelman, S. Sridhar, C. F. James, Y.-L. Chiu, B. L. Pilmer, R. G. Keith & R. H. Hunt*

435 Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn. *M. Robinson, S. Rodriguez-Stanley, P. B. Miner, A. J. McGuire, K. Fung & A. A. Ciociola*

445 Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. *M. Robinson, S. Fitzgerald, R. Hegedus, A. Murthy, L. Jokubaitis & (on behalf of the FAST trial investigators)*

455 Integrated acidity and rabeprazole pharmacology. *J. D. Gardner, C. Perdomo, S. Sloan, W. F. Hahne, J. A. Barth, S. Rodriguez-Stanley & M. Robinson*

465 Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. *W. -M. Wong, K. C. Lai, C. P. Lau, W. H. C. Hu, W. H. Chen, B. C. Y. Wong, W. M. Hui, Y. H. Wong, H. H. X. Xia & S. K. Lam*

473 Over-the-counter $H_2$-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors. *R. Tutuian, P. O. Katz, F. Ahmed, S. Korn & D. O. Castell*

479 A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. *G. Holtmann, P. Bytzer, M. Metz, V. Loeffler & A. L. Blum*

487 *Helicobacter pylori* and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits. *H. J. O'Connor*

497 Interactions between *Helicobacter pylori* and other risk factors for peptic ulcer bleeding. *W. A. Stack, J. C. Atherton, G. M. Hawkey, R. F. A. Logan & C. J. Hawkey*

507 Role of *Helicobacter pylori* serology in atrophic body gastritis after eradication treatment. *E. Lahner, C. Bordi, E. Di Giulio, P. Caruana, G. D'Ambra, M. Milione, C. Grossi, G. Delle Fave & B. Annibale*

515 The effect of *Helicobacter pylori* eradication on the natural course of atrophic gastritis with dysplasia. *A. Kokkola, P. Sipponen, H. Rautelin, M. Härkönen, T. U. Kosunen, R. Haapiainen & P. Puolakkainen*

521 Optimal serological tests for the detection of *Helicobacter pylori* infection in the Chinese population. *H. H.-X. Xia, B. C. Y. Wong, W. M. Wong, V. S. Y. Tang, H. K. L. Cheung, F. N. F. Sham, F. M. Y. Fung, K. C. Lai, W. H. C. Hu, C. K. Chan & S. K. Lam*

527 Mono, dual and triple moxifloxacin-based therapies for *Helicobacter pylori* eradication. *S. Di Caro, V. Ojetti, M. A. Zocco, F. Cremonini, F. Bartolozzi, M. Candelli, A. Lupascu, E. C. Nista, G. Cammarota & A. Gasbarrini*

533 Specific identification of three low molecular weight membrane-associated antigens of *Helicobacter pylori*. *P. Voland, D. L. Weeks, D. Vaira, C. Prinz & G. Sachs*

545 Effect of *Helicobacter pylori* eradication on oesophageal acid exposure in patients with reflux oesophagitis. *J. C. Y. Wu, F. K. L. Chan, S. K. H. Wong, Y. T. Lee, W. K. Leung & J. J. Y. Sung*

553 Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the $^{13}$C-urea breath test. *F. Parente, M. Sainaghi, O. Sangaletti, V. Imbesi, G. Maconi, A. Anderloni & G. Bianchi Porro*

559 The cost-effectiveness of population *Helicobacter pylori* screening and treatment: a Markov model using economic data from a randomized controlled trial. *J. Mason, A. T. R. Axon, D. Forman, S. Duffett, M. Drummond, W. Crocombe, R. Feltbower, S. Mason, J. Brown, P. Moayyedi & (on behalf of the Leeds HELP Study Group)*

569 Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, *Helicobacter pylori* eradication therapies. *S. D. Georgopoulos, S. D. Ladas, S. Karatapanis, K. Triantafyllou, C. Spiliadi, A. Mentis, V. Artikis & S. A. Raptis*

577 Influence of *Helicobacter pylori* infection and eradication on blood lipids and fibrinogen. *J. I. Elizalde, J. M. Piqué, V. Moreno, J. D. Morillas, I. Elizalde, L.Bujanda, C. M. De Argila, A. Cosme, A. Castiella, E. Ros, (for the Group of Study of Oesophageal & Gastric Diseases from the Spanish Gastroenterological Association)*

587 *Bifidobacterium animalis* strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. *P. Marteau, E. Cuillerier, S. Meance, M. F. Gerhardt, A. Myara, M. Bouvier, C. Bouley, F. Tondu, G. Bommelaer & J. C. Grimaud*

595 Albendazole chemotherapy for AIDS-related diarrhoea in Zambia – clinical, parasitological and mucosal responses. *I. Zulu, A. Veitch, S. Sianongo, G. McPhail, R. Feakins, M. J. G. Farthing & P. Kelly*

603 The effects of the specific $5HT^4$ receptor agonist, prucalopride, on colonic motility in healthy volunteers. *A. M. P. De Schryver, G. I. Andriesse, M. Samsom, A. J. P. M. Smout, H. G. Gooszen & L. M. A. Akkermans*

613 Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. *E. Distrutti, S. Fiorucci, S. K. Hauer, M. O. Pensi, M. Vanasia & A. Morelli*

623 Effect of granisetron on radiation-induced alterations of colonic motility and fluid absorption in rats. *C. Picard, B. Ksas, N. M. Griffiths & J. Fioramonti*

633 Lectins can reverse the distal intestinal atrophy associated with elemental diets in mice. *M. Sasaki, A. J. FitzGerald, G. Grant, M. A. Ghatei, N. A. Wright & R. A. Goodlad*

643 Letters to the Editors. *F. De Ponti, R. De Giorgio; M. C. Bateson; H. K. Parsons; P. Netzer & W. Inauen*

VOLUME 16 NUMBER 4 APRIL


647 Review article: monitoring for drug side-effects in inflammatory bowel disease. *R. N. Cunliffe & B. B. Scott*

663 Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. *A. J. Wakefield, J. M. Puleston, S. M. Montgomery, A. Anthony, J. J. O'Leary & S. H. Murch*

675 Review article: faecal markers in the assessment of activity in inflammatory bowel disease. *A. Poullis, R. Foster, T. C. Northfield & M. A. Mendall*

683 Review article: an approach to *Helicobacter pylori* infection in the elderly. *A. Pilotto & P. Malfertheiner*

693 The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. *A. G. Fraser, D. Morton, D. McGovern, S. Travis & D. P. Jewell*

699 A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. *F. H. Gordon, M. I. Hamilton, S. Donoghue, C. Greenlees, T. Palmer, D. Rowley-Jones, A. P. Dhillon, P. L. Amlot & R. E. Pounder*

707 Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. *F. V. Schiødt, W. M. Lee, S. Bondesen, P. Ott & E. Christensen*

717 $^{13}$C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. *E. Giannini, A. Fasoli, B. Chiarbonello, F. Malfatti, P. Romagnoli, F. Botta, E. Testa, S. Polegato, A. Fumagalli & R. Testa*

727 Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?. *B. F. Thompson, M. R. Arguedas & C. M. Wilcox*

735 There are no reliable symptoms for erosive oesophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential. *B. Avidan, A. Sonnenberg, T. G. Schnell & S. J. Sontag*

743 Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. *N. Pehlivanov, I. Sarosiek, R. Whitman, M. Olyaee & R. McCallum*

749 Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. *C. L. Chen, W. C. Orr, M. H. Verlinden, A. Dettmer, H. Brinkhoff, D. Riff, S. Schwartz, R. D. Soloway, R. Krause, F. Lanza & R. J. Mack*

759 Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. *C. E. J. Sloots, A. C. Poen, R. Kerstens, M. Stevens, M. De Pauw, J. C. Van Oene, S. G. M. Meuwissen & R. J. F. Felt-Bersma*

769 Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum *in vivo*. *C. Högenauer, B. Aichbichler, C. Santa Ana, J. Porter & J. Fordtran*

779 *Helicobacter pylori* increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. *A. Lanas, J. Fuentes, R. Benito, P. Serrano, E. Bajador & R. Sáinz*

787 The $^{13}$C-urea breath test to detect *Helicobacter pylori* infection: a validated simple methodology with 50 mg $^{13}$C-urea. *C.-C. Liao, C.-L. Lee, T.-C. Chiang, S.-C. Lee, S.-H. Huang, T.-C. Tu, T.-K. Chen & C.-H. Wu*

793 One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of *Helicobacter pylori* eradication with standard triple therapies. *W. M. Wong, B. C. Y. Wong, H. Lu, Q. Gu, Y. Yin, W. H. Wang, F. M. Y. Fung, K. C. Lai, H. H. X. Xia, S. D. Xiao & S. K. Lam*

799 Effect of Helicobacter pylori infection and its eradication on nutrition. *T. Furuta, N. Shirai, F. Xiao, M. Takashima & H. Hanai*

807 Serum pepsinogen and gastrin levels in HIV- positive patients: relationship with CD4+ cell count and *Helicobacter pylori* infection. *P. Fabris, A. Pilotto, L. Bozzola, G. Tositti, G. Soffiati, V. Manfrin & F. de Lalla*

813 An evaluation of a rapid urine test for the diagnosis of *Helicobacter pylori* infection in the Chinese population. *W. M. Wong, B. C. Y. Wong, H. H. X. Xia, V. S. Y. Tang, K. C. Lai, W. H. C. Hu, M. F. Yuen, C. K. Chan & S. K. Lam*

819 Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. *J. L. Goldstein, G. M. Eisen, T. A. Burke, B. M. Peña, J. Lefkowith & G. S. Geis*

829 Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. *R. Tutuian, P. O. Katz, W. Bochenek & D. O. Castell*

837 Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night- time in different CYP2C19 genotype groups. *N. Shirai, T. Furuta, F. Xiao, M. Kajimura, H. Hanai, K. Ohashi & T. Ishizaki*

847 Inhibition of *Helicobacter pylori* -induced cyclo- oxygenase- 2 aggravates NSAID- caused gastric damage in Mongolian gerbils. *S. Futagami, T. Hiratsuka, K. Wada, A. Tatsuguchi, T. Tsukui, K. Miyake, T. Akamatsu, M. Hosone, C. Sakamoto & M. Kobayashi*

VOLUME 16 NUMBER 5 MAY

857 Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? *I. D. R.Arnott, D. Watts & S. Ghosh*

869 Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. *L. Cange, E. Johnsson, H. Rydholm, A. Lehmann, C. Finizia, L. Lundell & M. Ruth*

875 A modification of the quininium resin test for assessing gastric acidity. *D. J. Passaro, A. Hurwitz, G. Triadafilopoulos & J. Parsonnet*

881 Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. *M. Frazzoni, E. De Micheli, A. Grisendi & V. Savarino*

887 Corpus gastritis in patients with endoscopic diagnosis of reflux oesophagitis and Barrett's oesophagus. *R.J.F. Laheij, L. G. M. Van Rossum, W. A. De Boer & J. B. M. J. Jansen*

893 Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. *P. Zentilin, M. Conio, M. R. Mele, C. Mansi, N. Pandolfo, P. Dulbecco, C. Gambaro, L. Tessieri, E. Iiritano, C. Bilardi, R. Biagini, S. Vigneri & V. Savarino*

899 Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. *S. R. Orenstein, J. L. Blumer, H. M. Faessel, J. A. McGuire, K. Fung, B. U. K. Li, J. E. Lavine, J. E. Grunow, W. R. Treem & A. A. Ciociola*

909 Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. *T. Mimura, F. Rizzello, U. Helwig, G. Poggioli, S. Schreiber, I. C. Talbot, R. J. Nicholls, P. Gionchetti, M. Campieri & M. A. Kamm*

919 Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. *V. Abitbol, J. Y. Mary, C. Roux, J. C. Soulé, J. Belaiche, J.-L. Dupas, J. P. Gendre, E. Lerebours, S. Chaussade & the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)*

929 Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding? *C.-K. Hui, K.-C. Lai, M.-F. Yuen, W. -M. Wong, S.-K. Lam & C.-L. Lai*

937 Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy. *D. K. Rex, R. Chasen & M. B. Pochapin*

945 Acute effect of clonidine on gastric emptying in patients with diabetic gastropathy and controls. *V. Huilgol, J. Evans, R. S. Hellman & K. H. Soergel*

951 Domperidone is more effective than cisapride in children with diabetic gastroparesis. *A. Franzese, O. Borrelli, G. Corrado, P. Rea, G. Di Nardo, A. L. Grandinetti, L. Dito & S. Cucchiara*

959 Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. *B. Hallerbäck, G. Bommelaer, E. Bredberg, M. Campbell, M. Hellblom, K. Lauritsen, M. Wienbeck & L.-L. Holmgren*

969 Perceived food and drug allergies in functional and organic gastrointestinal disorders. *K. Bhat, A. Harper & D. A. Gorard*

975 Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study. *P. Svedberg, S. Johansson, M.-A. Wallander, B. Hamelin & N. L. Pedersen*

985 Blood antioxidant levels in patients with alcoholic liver disease correlate with the degree of liver impairment and are not specific to alcoholic liver injury itself. *M. Van De Casteele, Z. Zaman, M. Zeegers, R. Servaes, J. Fevery & F. Nevens*

993 Effect of alosetron on left colonic motility in nonconstipated patients with irritable bowel syndrome and healthy volunteers. *C. H. M. Clemens, M. Samsom, G. P. Van Berge Henegouwen, M. Fabri & A. J. P. M. Smout*

1003 General principles to enhance practice patterns in gastrointestinal endoscopy. *A. Sonnenberg & M.W. Gavin*

1011 Prospective audit of gastroscopy under the 'three-day rule': a regional initiative in Italy to reduce waiting time for suspected malignancy. *F. Parente, S. Bargiggia & G. Bianchi Porro*

1015 *Helicobacter pylori* infection, anti-cagA antibodies and peptic ulcer: a case–control study in Italy. *D. Palli, M. Menegatti, G. Masala, C. Ricci, C. Saieva, J. Holton, L. Gatta, M. Miglioli & D. Vaira*

1021 P- Glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. *R. J. Farrell, M. J. Menconi, A. C. Keates & C. P. Kelly*

1033 Letter to the Editors. *R. M. Klok, J. R. B. J. Brouwers, P. B. van den Berg, L. T. W. de Jong-van den Berg, K. Tolley & M. J. Postma*

1035 Corrigenda

VOLUME 16 NUMBER 6 JUNE

1037 Review article: *Helicobacter* species and hepatobiliary diseases. *R. W. L. Leong & J. J. Y. Sung*

1047 Review article: *Helicobacter pylori* 'rescue' regimen when proton pump inhibitor-based triple therapies fail. *J. P. Gisbert & J. M. Pajares*

1059 Review article: pathogenesis of sporadic and familial gastric cancer – implications for clinical management and cancer prevention. *M. P. A. Ebert & P. Malfertheiner*

1067 Peptic ulceration in general practice in England and Wales 1994–98: period prevalence and drug management. *J.-Y. Kang, A. Tinto, J. Higham & A. Majeed*

1075 The treatment of functional dyspepsia with red pepper. *M. Bortolotti, G. Coccia, G. Grossi & M. Miglioli*

1083 Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess. *F. H. Ng, W. M. Wong, B. C.Y. Wong, C. Kng, S.Y. Wong, K. C. Lai, C. S. Cheng, W. C. Yuen, S. K. Lam & C. L. Lai*

1091 Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. *M. R. Kraus, A. Schäfer, H. Faller, H. Csef & M. Scheurlen*

1101 Effects of anti-tumour necrosis factor-α therapy on the quality of life in Crohn's disease. *B. P.J. van Balkom, E. J. Schoon, R. W. Stockbrügger, F. L. Wolters, R. A. van Hogezand, S. J. H. van Deventer, B. Oldenburg, H. M. van Dullemen & M. G. V. M. Russel*

1109 Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. *F. Rizzello, P. Gionchetti, A. D'Arienzo, F. Manguso, G. Di Matteo, V. Annese, D. Valpiani, T. Casetti, S. Adamo, A. Prada, G. N. Castiglione, G. Varoli & M. Campieri*

1117 An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. *J. M. Sabate, J. Villarejo, M. Lemann, J. Bonnet, M. Allez & R. Modigliani*

1125 Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. *A. Barabino, F. Torrente, A. Ventura, S. Cucchiara, M. Castro & C. Barbera*

1131 A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. *S. J. Middleton, S. Naylor, J. Woolner & J. O. Hunter*

1137 Meta-analysis: the efficacy of intravenous $H^2$-receptor antagonists in bleeding peptic ulcer. *J. E. Levine, G. I. Leontiadis, V. K. Sharma & C. W. Howden*

1143 *Helicobacter pylori* eradication does not worsen quality of life related to reflux symptoms: a prospective trail. *L. Laine & V. Dhir*

1149 Single vs. double dose of a proton pump inhibitor in triple therapy for *Helicobacter pylori* eradication: a meta-analysis. *M. Vallve, M. Vergara, J. P. Gisbert & X. Calvet*

1157 Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. *R. Colin, for the HEPYLOG Investigator Study Group*

1163 Amoxicillin and ampicillin are not transferred to gastric juice irrespective of *Helicobacter pylori* status or acid blockade by omeprazole. *R. A. M. Ortiz, S.A. Calafatti, A. Corazzi, J. M. Souza, M. Deguer, C.A. F. De Souza, M. A. M. Marchioretto, G. Bernasconi, J. G. P. Ferraz & J. Pedrazzoli Jr*

1171 Health-related quality of life among persons with irritable bowel syndrome: a systematic review. *H. B. El-Serag, K. Olden & D. Bjorkman*

1187 Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. *S. A. Mitchell, A. S. Mee, G. D. Smith, K. R. Palmer & R. W. Chapman*

1197 Inguinal hernia is not a sign of colon cancer: results of a prospective screening trial. *B. Avidan, A. Sonnenberg, H. Bhatia, G. Aranha, T. G. Schnell & S. J. Sontag*

VOLUME 16 NUMBER 7 JULY

1203 Review article: *Helicobacter pylori* infection and gastric outlet obstruction — prevalence of the infection and role of antimicrobial treatment *J. P. Gisbert & J. M. Pajares*

1209 Review article: intestinal metaplasia and gastric carcinogenesis *W. K. Leung & J. J. Y. Sung*

1217 Review article: the burden of illness of non-cardiac chest pain *G. D. Eslick, D. S. Coulshed & N. J. Talley*

1225 Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine *A. G. Fraser, T. R. Orchard, E. M. Robinson & D. P. Jewell*

1233 Induction and maintenance of clinical remission by interferon-β in patients with steroid-refractory active ulcerative colitis—an open long-term pilot trial *E. Musch, T. Andus & M. Malek*

1241 The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment *J.-C. Luo, F.-Y. Chang, H.-Y. Lin, R.-H. Lu, C.-L. Lu, C.-Y. Chen & S.-D. Lee*

1249 Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading *M. Rugge, P. Correa, M. F. Dixon, R. Fiocca, T. Hattori, . J. Lechago, G. Leandro, A. B. Price, P. Sipponen, . E. Solcia, H. Watanabe & R. M. Genta*

1261 One-week triple vs. quadruple therapy for *Helicobacter pylori* infection — a randomized trial *X. Calvet, J. Ducons, J. Guardiola, L. Tito, V. Andreu, F. Bory, R. Guirao & The Group for Eradication Studies from Catalonia and Aragón (GRESCA)*

1269 Effectiveness of *Helicobacter pylori* eradication treatments in a primary care setting in Italy *P. Della Monica, A. Lavagna, G. Masoero, L. Lombardo, L. Crocellá, & A. Pera*

1277 Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of *Helicobacter pylori* resistant to metronidazole *V. Isakov, I. Domareva, L. Koudryavtseva, I. Maev & Z. Ganskaya*

1283 Evaluation of *Helicobacter pylori* diagnostic methods in patients with liver cirrhosis *X. Calvet, I. Sanfeliu, E. Musulen, P. Mas, B. Dalmau, M. Gil, M. R. Bella, R. Campo, E. Brullet, C. Valero & J. Puig*

1291 Eradication of *Helicobacter pylori* may reduce disease severity in rheumatoid arthritis *P. Zentilin, B. Seriolo, P. Dulbecco, E. Caratto, E. Iiritano, D. Fasciolo, C. Bilardi, C. Mansi, E. Testa & V. Savarino*

1301 Effects of rabeprazole, 20mg, or esomeprazole, 20mg, on 24-h intragastric pH and serum gastrin in healthy subjects *S. Warrington, K. Baisley, M. Boyce, B. Tejura, A. Morocutti & N. Miller*

1309 An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy *U. C. Nzeako & J. A. Murray*

1317 Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity *J. D.Gardner, A. A. Ciociola, M. Robinson & R.L. McIsaac*

1327 Low-salt bowel cleansing preparation (LoSo Prep) as preparation for colonoscopy: a pilot study *V. J. Verghese, K. Ayub, W. Qureshi, T. Taupo & D. Y. Graham*

1333 Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years *C. Hallert, C. Grant, S. Grehn, C. Grännö, S. Hultén, G. Midhagen, M. Ström, H. Svensson & T. Valdimarsson*

1341 Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control *B. Braden, M. Enghofer, M. Schaub, K.-H. Usadel, W. F. Caspary & B. Lembcke*

1347 Prucalopride, a systemic enterokinetic, for the treatment of constipation *A. V. Emmanuel, A. J. Roy, T. J. Nicholls & M. A. Kamm*

1357 The effect of the 5-$HT_3$ receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients *E. A. Mayer, S. Berman, S. W. G. Derbyshire, B. Suyenobu, L. Chang, L. Fitzgerald, M. Mandelkern, L. Hamm, B. Vogt & B. D. Naliboff*

1367 Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas *S. Bashir, F. Gibril, J. V. Ojeaburu, B. Asgharian, L. K. Entsuah, G. Ferraro, P. Crafa, C. Bordi & R. T. Jensen*

VOLUME 16 NUMBER 8 AUGUST

1383 Review article: the role of the gut flora in health and disease, and its modification as therapy. *A. L. Hart, A. J. Stagg, M. Frame, H. Graffner, H. Glise, P. Falk & M. A. Kamm*

1395 Review article: the treatment of irritable bowel syndrome. *W. G. Thompson*

1407 Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. *M. Camilleri, R. C. Heading & W. G. Thompson*

1431 Impact of *Helicobacter pylori* eradication on heartburn in patients with gastric or duodenal ulcer disease — results from a randomized trial programme. *P. Malfertheiner, J. Dent, L. Zeijlon, P. Sipponen, S. J. O. Veldhuyzen van Zanten, C.-F. Burman, T. Lind, M. Wrangstadh, E. Bayerdörffer & J. Lonovics*

1443 Appropriateness of urea breath test: a prospective observational study based on Maastricht 2000 guidelines. *F. Perri, R. Ricciardi, A. Merla, A. Piepoli, V. Gasperi, M. Quitadamo & A. Andriulli*

1449 *Helicobacter pylori* eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. *M. Ito, K. Haruma, T. Kamada, M. Mihara, S. Kim, Y. Kitadai, M. Sumii, S. Tanaka, M. Yoshihara & K. Chayama*

1457 Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for *Helicobacter pylori* infection. *D. Boixeda, F. Bermejo, C. Martín-De-Argila, A. López-Sanromán, V. Defarges, F. Hernández-Ranz, J. M. Milicua & A. García-Plaza*

1461 Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. *F. Cremonini, S. Di Caro, E. C. Nista, F. Bartolozzi, G. Capelli, G. Gasbarrini & A. Gasbarrini*

1469 Systematic review: patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease. *N. Vakil, T. Rydén-Bergsten & K. Bergenheim*

1481 Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. *P. Netzer, B. Schmitt & W. Inauen*

1491 Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. *U. Ladabaum, W. D. Chey, J. M. Scheiman & A. M. Fendrick*

1503 The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. *A. Barabino, F. Torrente, E. Castellano, P. Gandullia, A. Calvi, S. Cucchiara, G. L. de'Angelis, M. Fontana, P. Lionetti, C. De Giacomo & A. Gissi*

1509 Systematic review: the effectiveness of budesonide therapy for Crohn's disease. *S. V. Kane, P. Schoenfeld, W. J. Sandborn, W. Tremaine, T. Hofer & B. G. Feagan*

1519 Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. *R. W. Stockbrügger, E. J. Schoon, S. Bollani, P. R. Mills, E. Israeli, L. Landgraf, D. Felsenberg, S. Ljunghall, G. Nygard, T. Persson, H. Graffner, G. Bianchi Porro & A. Ferguson*

1529 Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case–control study with cost analysis. *J. Gournay, J. Tchuenbou, C. Richou, C. Masliah, F. Lerat, B. Dupas, T. Martin, J. F. Nouel, M. Schnée, P. Montigny, A. D'Alincourt, A. Hamy, J. Paineau, J.-C. Le Néel, J. Le Borgne & J. P. Galmiche*

1539 The effect of regular medication on the outcome of paracetamol poisoning. *L. E. Schmidt & K. Dalhoff*

1547 Serum bile acids in patients with liver failure supported with a bioartificial liver. *P. Pazzi, E. Morsiani, M. T. Vilei, A. Granato, J. Rozga, A. A. Demetriou & M. Muraca*

1555 Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients. *H. Van Vlierberghe, H. Verdievel, I. Colle, J. Delanghe, M. Praet, D. Bernard, G. Leroux-Roels & M. De Vos*

1563 Octreotide enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects. *E. Athanasakis, E. Chrysos, O. J. Zoras, J. Tsiaoussis, N. Karkavitsas & E. Xynos*

1571 Magnesium chloride slows gastric emptying, but does not affect digestive functions. *K. P. Geboes, B. Maes, A. Luypaerts, P. Evenepoel, P. Rutgeerts, Y. Ghoos & B. Geypens*

VOLUME 16 NUMBER 9 SEPTEMBER

1579 Review article: biological agents in the treatment of Crohn's disease. *R. Caprilli, A. Viscido & D. Guagnozzi*

1591 Review article: lactose — a potential prebiotic. *A. Szilagyi*

1603 The quality of life in patients with Crohn's disease. *R. D. Cohen*

1611 Meta-analysis: combination therapy with interferon-α 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. *R. San Miguel, F. Guillén, J. M. Cabasés & M. Buti*

1623 Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. *C. H. Chang, K. Y. Chen, M. Y. Lai & K. A. Chan*

1633 Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. *G. B. Gaeta, D. F. Precone, F. M. Felaco, R. Bruno, A. Spadaro, G. Stornaiuolo, M. Stanzione, T. Ascione, R. De Sena, A. Campanone, G. Filice & F. Piccinino*

1641 A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. *G. Holtmann, J. Gschossmann, P. Mayr & N. J. Talley*

1649 Naloxone treatment for irritable bowel syndrome — a randomized controlled trial with an oral formulation. *N. D. Hawkes, J. Rhodes, B. K. Evans, P. Rhodes, A. B. Hawthorne & G. A. O. Thomas*

1655 The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. *M. A. Van Herwaarden, M. Samsom, H. Rydholm & A. J. P. M. Smout*

1663 Dynamics of *Helicobacter pylori* infection in early childhood in a high-risk group living in Germany: loss of infection higher than acquisition. *D. Rothenbacher, G. Bode & H. Brenner*

1669 Impact of supplement with *Lactobacillus*- and *Bifidobacterium*-containing yogurt on triple therapy for *Helicobacter pylori* eradication. *B. -S. Sheu, J. -J. Wu, C.-Y. Lo, H. -W. Wu, J. -H. Chen, Y. -S. Lin & M. -D. Lin*

1677 Foetal intrauterine growth restrictions with *Helicobacter pylori* infection. *G. D. Eslick, P. Yan, H. H.-X. Xia, H. Murray, B. Spurrett & N. J. Talley*

1683 Effects of enteric-coated, low-dose aspirin on parameters of platelet function. *A. Van Hecken, M. L. Juliano, M. Depré, I. De Lepeleire, J. Arnout, A. Dynder, L. Wildonger, K. J. Petty, K. Gottesdiener & J. N. De Hoon*

VOLUME 16 NUMBER 10 OCTOBER

1689 Systematic review: herbal medicinal products for non-ulcer dyspepsia. *J. Thompson Coon & E. Ernst*

1701 Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. *G. Tougas, W.J. Snape Jr, M. H. Otten, D. L. Earnest, K.-E. Langaker, R. E. Pruitt, E. Pecher, B. Nault & M. A. Rojavin*

1709 Alimentary diseases in the poor and middle class in London 1773–1815, and in New York poor 1797–1818. *J. H. Baron & A. Sonnenberg*

1715 The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. *G. Caletti, P. L. Zinzani, P. Fusaroli, E. Buscarini, F. Parente, T. Federici, S. Peyre, C. De Angelis, G. Bonanno, T. Togliani, S. Pileri, S. Tura & The Italinan Gastric Lymphoma Study Group*

1723 The long-term effects of cure of *Helicobacter pylori* infection on patients with atrophic body gastritis. *B. Annibale, E. Di Giulio, P. Caruana, E. Lahner, G. Capurso, C. Bordi & G. Delle Fave*

1733 Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of *Helicobacter pylori* infection. *C. Bilardi, R. Biagini, P. Dulbecco, E. Iiritano, C. Gambaro, M. R. Mele, P. Borro, L. Tessieri, P. Zentilin, C. Mansi, S. Vigneri & V. Savarino*

1739 Efficacy of enzyme immunoassay for the detection of *Helicobacter pylori* antigens in frozen stool specimens: local validation. *Y. K. Yee, K. T. Yip, T. L. Que, K. K. Chang, K. F. Li, C. K. Lee, S. W. Wong, S. F. Lau & M. L. Szeto*

1743 Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. *A. Ansari, C. Hassan, J. Duley, A. Marinaki, E.-M. Shobowale-Bakre, P. Seed, J. Meenan, A. Yim & J. Sanderson*

1751 Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. *O. A. Paoluzi, R. Pica, A. Marcheggiano, P. Crispino, F. Iacopini, C. Iannoni, M. Rivera & P. Paoluzi*

1761 Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. *B. R. Yacyshyn, C. Barish, J. Goff, D. Dalke, M. Gaspari, R. Yu, J. Tami, F. A. Dorr & K. L. Sewell*

1771 Colonic delivery of 4-aminosalicylic acid using amylose–ethylcellulose-coated hydroxypropylmethylcellulose capsules. *C. Tuleu, A. W. Basit, W.A. Waddington, P. J. Ell & J. M. Newton*

1781 Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. *F. Cremonini, B. P. Mullan, M. Camilleri, D. D. Burton & M. R. Rank*

1791 Gabexate mesilate and/or octreotide in human immunodeficiency virus-associated pancreatic abnormalities. *R. Manfredi, L. Calza & F. Chiodo*

1795 Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. *S. J. Spechler, S. K. Jain, D. A. Tendler & R. A. Parker*

1801 Prokinetic effect of indoramin, an α-adrenergic antagonist, on human gall-bladder. *S. Sengupta, R. Cooney, M. Baj, R. Ni'Muircheartaigh & L. J. D. O'Donnell*

1805 Serum pepsinogen can predict response to H2-receptor antagonist in patients with functional dyspepsia. *I. Yoshikawa, I. Murata, K. Kume, K. Kanagawa, Y. Hirohata, H. Nakamura & M. Otsuki*

1811 Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. *T. Saitoh, Y. Fukushima, H. Otsuka, J. Hirakawa, H. Mori, T. Asano, T. Ishikawa, T. Katsube, K. Ogawa & S. Ohkawa*

1819 Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. *J. D. Gardner, S. Rodriguez-Stanley, M. Robinson & P. B. Miner, Jr*

1831 Letters to the Editors. *S. Massironi, A. Losco & G. Basilisco: A. C. B. Wicks, C. Thomas, R. Curran & J. F. Mayberry*

VOLUME 16 NUMBER 11 NOVEMBER

1833 Review article: adult-to-adult right hepatic lobe living donor liver transplantation. *P. H. Hayashi & J. F. Trotter*

1843 Review article: genetic testing and counselling for hereditary colorectal cancer. *J. D. Trimbath & F. M. Giardiello*

1859 Review article: gastroenterology and the pharmaceutical industry. *H. Rakatansky*

1867 Review article: bloating in functional bowel disorders. *S. Zar, M. J. Benson & D. Kumar*

1877 A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. *J. Novick, P. Miner, R. Krause, K. Glebas, H. Bliesath, G. Ligozio, P. Rüegg & M. Lefkowitz*

1889 Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. *G. Rubin, A. P. S. Hungin, D. Chinn, A. D. Dwarakanath, L. Green & J. Bates*

1895 Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. *E. J. Lamb, T. Wong, D. J. Smith, D. E. Simpson, A. J. Coakley, C. Moniz & A. F. Muller*

1903 Gut mucosal response to food antigens in Crohn's disease. *J. Van Den Bogaerde, J. Cahill, A. V. Emmanuel, C. J. Vaizey, I. C. Talbot, S. C. Knight & M. A. Kamm*

1917 Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. *Z. Khan, C. MacDonald, A. C. Wicks, M. P. Holt, D. Floyd, S. Ghosh, N. A. Wright & R. J. Playford*

1923 Alteration of histological gastritis after cure of *Helicobacter pylori* infection. *M. Hojo, H. Miwa, T. Ohkusa, R. Ohkura, A. Kurosawa & N. Sato*

1933 Eradication rates of clarithromycin-resistant *Helicobacter pylori* using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. *K. Murakami, R. Sato, T. Okimoto, M. Nasu, T. Fujioka, M. Kodama, J. Kagawa, S. Sato, H. Abe & T. Arita*

1939 Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. *L. L. Lim, C. T. Wai, Y. M. Lee, H. L. Kong, R. Lim, E. Koay & S. G. Lim*

1945 Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. *P. Serrano, A. Lanas, M. T. Arroyo & I. J. Ferreira*

1955 Effect of the low-affinity, noncompetitive N-methyl-D-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. *S. D. Kuiken, A. Lei, G. N. J. Tytgat, R. Holman & G. E. E. Boeckxstaens*

VOLUME 16 NUMBER 12 DECEMBER

1963 Review article: haemochromatosis. *C. A. Whittington & K. V. Kowdley*

1977 Review article: breath testing for human liver function assessment. *A. Armuzzi, M. Candelli, M. A. Zocco, A. Andreoli, A. De Lorenzo, E. C. Nista, L. Miele, F. Cremonini, I. A. Cazzato, A. Grieco, G. Gasbarrini & A. Gasbarrini*

1997 Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease — radicals or ridiculous? *L. Kruidenier & H. W. Verspaget*

2017 Review article: mechanisms of initiation and perpetuation of gut inflammation by stress. *A. Hart & M. A. Kamm*

2029 Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control *K. L. Collings, S. Rodriguez-Stanley, H. M. Proskin, M. Robinson & P. B. Miner Jr*

2037 Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese — prevalence and spectrum of the disease. *W.-M. Wong, S. K. Lam, W. M. Hui, K. C. Lai, C. K. Chan, W. H. C. Hu, H. H. X. Xia, C. K. Hui, M. F. Yuen, A. O. O. Chan & B. C. Y. Wong*

2043 Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. *T. O. G. Kovacs, C. M. Wilcox, K. Devault, D. Miska, W. Bochenek & The Pantoprazole US GERD Study Group B*

2053 Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds. *I. S. Shaw, B. A. Jobson, D. Silverman, J. Ford, S. D. Hearing, D. Ball, E. Johnson, A. Day & C. S. J. Probert*

2061 Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. *E. Domènech, E. Garcia-Planella, I. Bernal, M. Rosinach, E. Cabré, L. Fluvià, J. Boix & M. A. Gassull*

2067 One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of *Helicobacter pylori* infection in Chinese. *W. K. Hung, W. M. Wong, G. S. W. Wong, A. W. C. Yip, M. L. Szeto, K. C. Lai, W. H. C. Hu, C. K. Chan, H. H. X. Xia, M. F. Yuen, F. M. Y. Fung, T. S. M. Tong, V. Y. K. Ho, S. K. Lam & B. C. Y. Wong*

2073 Fluorescence *in situ* hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant *Helicobacter pylori* strains in gastric biopsies from children. *A. Feydt-Schmidt, H. Rüssmann, N. Lehn, A. Fischer, I. Antoni, D. Störk & S. Koletzko*

2081 Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. *W. H. C. Hu, W.-M. Wong, C. L. K. Lam, K. F. Lam, W. M. Hui, K. C. Lai, H. X. H. Xia, S. K. Lam & B. C. Y. Wong*

2089 Arthritis treatment in Hong Kong — cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. *J. H. S. You, K. K. C. Lee, T. Y. K. Chan, W. H. Lau & F. K. L. Chan*

2097 Acute and chronic pancreatitis — diseases on the rise: a study of hospital admissions in England 1989/90–1999/2000. *A. Tinto, D. A. J. Lloyd, J.-Y. Kang, A. Majeed, C. Ellis, R. C. N. Williamson & J. D. Maxwell*

2107 High-dose interferon α-2a with ribavirin and amantadine in naïve chronic hepatitis C patients — results of a randomized, prospective, pilot study. *H. Ullerich, W. Avenhaus, C. Poremba, W. Domschke & J. Menzel*

2115 A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis. *P. M. Ginsburg & E. D. Ehrenpreis*